PekCura Labs
Has PekCura Labs received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026.
Letter facts
- Letter date
- March 31, 2026 (2026-03-31)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Online / Internet Pharmacy
- Products named
- GLP-1-S (all variations)GLP-2-T (all variations)GLP-3-R (all variations)Bacteriostatic Water (all variations)Cag (1mg) Tirz (10mg) Blend
- Violation categories
- Unapproved new drug
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Factual Violation Summary
FDA determined PekCura Labs' GLP-1-S, GLP-2-T, GLP-3-R, and Bacteriostatic Water are unapproved new drugs intended for human use; no approved applications are in effect, violating FD&C Act sections 505(a) and 301(d).
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Unapproved new drugs
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.